Hyperphosphatemia Treatment Market Report 2025

This Hyperphosphatemia Treatment market report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The hyperphosphatemia treatment market size has grown rapidly in recent years. It will grow from $4.56 billion in 2024 to $5.13 billion in 2025 at a compound annual growth rate (CAGR) of 12.4%. The growth in the historic period can be attributed to increased incidence of chronic kidney disease (CKD), growth in aging population, high prevalence of diabetes and hypertension, expansion of dialysis patient population, advances in medical research and diagnosis of hyperphosphatemia.

The hyperphosphatemia treatment market size is expected to see rapid growth in the next few years. It will grow to $8.56 billion in 2029 at a compound annual growth rate (CAGR) of 13.7%. The growth in the forecast period can be attributed to rise in lifestyle-related diseases contributing to hyperphosphatemia, continued growth in aging demographics, increasing awareness and diagnosis of hyperphosphatemia, expansion of emerging markets with high disease burden, higher prescription share of calcium-based phosphate binders in emerging countries. Major trends in the forecast period include advancements in hyperphosphatemia treatment technologies, integration of telehealth and remote patient monitoring, collaborations and partnerships for research and development, focus on patient education and lifestyle management in hyperphosphatemia, development of novel phosphate binders and therapies.

The growth of the hyperphosphatemia treatment market is being fueled by the increasing prevalence of chronic diseases among patients, which require long-term care. Chronic diseases, including cardiovascular diseases, chronic kidney disease, chronic respiratory conditions, hyperparathyroidism, diabetes, and cancer, contribute to a significant portion of global deaths, with 74% attributed to non-communicable diseases (NCDs) or chronic diseases, as reported by the World Health Organization in September 2023. Notably, kidney diseases are on the rise, with untreated kidney failure claiming the lives of approximately 1 million individuals each year, according to SingleCare Services LLC in February 2023. The escalating cases of hyperphosphatemia in patients with end-stage renal disease (ESRD) are driving the demand for hyperphosphatemia treatment drugs.

The rise in dietary modifications is anticipated to drive the growth of the hyperphosphatemia treatment market in the future. Dietary modifications refer to intentional alterations made to a person's eating habits or diet to achieve specific health, nutritional, or lifestyle objectives. These modifications can significantly aid in managing hyperphosphatemia, helping to control phosphate levels, prevent complications, reduce reliance on medication, promote overall health, and enhance quality of life. For example, in 2023, the International Food Information Council, a US-based organization, reported a notable increase in the number of boomers following specific eating patterns or diets, with the figure rising to 41%, up from 29% in 2022. Therefore, the growing trend of dietary modifications is fueling the expansion of the hyperphosphatemia treatment market.

The growing emphasis on research and development activities is a significant trend in the hyperphosphatemia treatment market. Companies involved in hyperphosphatemia treatment are concentrating on R&D to create innovative therapies for renal diseases and associated chronic conditions. For example, in April 2024, Eurostat, a European governmental agency, reported that in 2023, the Ile-de-France region in France had 2.4 million core human resources dedicated to science and technology, the highest number in Europe. The Comunidad de Madrid region in Spain followed with 1.2 million.

Major companies in the hyperphosphatemia treatment market are concentrating on the development of innovative products, such as Xphozah, to drive market revenues. Xphozah, designed to treat hyperphosphatemia, addresses the excessive phosphorus causing calcium removal from bones and various body parts. In October 2023, Ardelyx Inc., a US-based biopharmaceutical company, received FDA approval for Xphozah. This approval is for the treatment of hyperphosphatemia in patients unresponsive or intolerant to current standard-of-care phosphate binder therapies.

In May 2023, South Africa-based healthcare services group Life Healthcare Group Holdings Limited acquired Fresenius Medical Care AG and Co. KGaA for an undisclosed amount. This strategic acquisition enhances Life Healthcare's offerings in acute and ongoing renal dialysis treatments in South Africa. With the acquisition, Life Healthcare aims to play a vital role in ensuring the continuity of existing patient care plans. Fresenius Medical Care AG and Co. KGaA, a Germany-based company manufacturing hyperphosphatemia treatment drugs, is now part of Life Healthcare Group Holdings Limited.

Major companies operating in the hyperphosphatemia treatment market include Sanofi SA, Akebia Therapeutics Inc., Ardelyx Inc., Astellas Pharma Inc., Fresenius Medical Care AG & Co. KGaA, Lupin Limited, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Ultragenyx Pharmaceutical Inc., Unicycive Therapeutics Inc., Vifor Pharma Management Ltd., Zeria Pharmaceutical Co. Ltd., Amgen Inc., AstraZeneca plc, Baxter International Inc., Beckman Coulter Inc., Cleveland Clinic, DaVita Inc., Kyowa Kirin Pharmaceuticals Co. Ltd., Mayo Clinic, OPKO Health Inc., Tenet Healthcare Corporation, UnitedHealth Group Inc.

North America was the largest region in the hyperphosphatemia treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hyperphosphatemia treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hyperphosphatemia treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

Hyperphosphatemia treatment involves a class of drugs designed to enhance renal excretion for managing patients with elevated levels of phosphates. The most effective method is through volume replenishment using saline and forced diuresis with a loop diuretic such as furosemide or bumetanide.

The primary products in the hyperphosphatemia treatment market include sevelamer, calcium-based phosphate binders, iron-based phosphate binders, lanthanum carbonate, and others. The sevelamer market comprises sales of sevelamer products by entities (organizations, partnerships, and sole traders). Sevelamer is a phosphate-binding medication used to treat hyperphosphatemia in patients with chronic kidney diseases. The distribution of hyperphosphatemia treatment occurs through various channels, including hospital pharmacies, retail pharmacies, and online stores. In terms of dosage form, it is segmented into capsules, tablets, and syrups.

The hyperphosphatemia treatment market research report is one of a series of new reports that provides hyperphosphatemia treatment market statistics, including hyperphosphatemia treatment industry global market size, regional shares, competitors with a hyperphosphatemia treatment market share, detailed hyperphosphatemia treatment market segments, market trends and opportunities, and any further data you may need to thrive in the hyperphosphatemia treatment industry. This hyperphosphatemia treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The hyperphosphatemia treatment market includes revenues earned by lowering the phosphate load and maintaining serum phosphorus levels within the normal range. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.